09:19:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-12-05 Årsstämma 2025
2024-11-05 Bokslutskommuniké 2024
2024-08-20 Kvartalsrapport 2024-Q3
2024-05-07 Kvartalsrapport 2024-Q2
2024-02-09 Kvartalsrapport 2024-Q1
2023-12-07 Årsstämma 2024
2023-11-09 Bokslutskommuniké 2023
2023-08-17 Kvartalsrapport 2023-Q3
2023-05-15 Halvårsutdelning COLO B 5
2023-05-11 Kvartalsrapport 2023-Q2
2023-02-03 Kvartalsrapport 2023-Q1
2022-12-02 Halvårsutdelning COLO B 15
2022-12-01 Årsstämma 2023
2022-11-07 Bokslutskommuniké 2022
2022-08-17 Kvartalsrapport 2022-Q3
2022-05-09 Halvårsutdelning COLO B 5
2022-05-05 Kvartalsrapport 2022-Q2
2022-01-25 Kvartalsrapport 2022-Q1
2021-12-03 Halvårsutdelning COLO B 14
2021-12-02 Årsstämma 2022
2021-11-01 Bokslutskommuniké 2021
2021-08-18 Kvartalsrapport 2021-Q3
2021-05-10 Halvårsutdelning COLO B 5
2021-05-06 Kvartalsrapport 2021-Q2
2021-02-06 Kvartalsrapport 2021-Q1
2020-12-04 Halvårsutdelning COLO B 13
2020-12-03 Årsstämma 2021
2020-11-03 Bokslutskommuniké 2020
2020-08-18 Kvartalsrapport 2020-Q3
2020-05-11 Halvårsutdelning COLO B 5
2020-05-06 Kvartalsrapport 2020-Q2
2020-02-06 Kvartalsrapport 2020-Q1
2019-12-06 Halvårsutdelning COLO B 12
2019-12-05 Årsstämma 2020
2019-11-05 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q3
2019-05-06 Halvårsutdelning COLO B 5
2019-05-02 Kvartalsrapport 2019-Q2
2019-02-05 Kvartalsrapport 2019-Q1
2018-12-06 Halvårsutdelning COLO B 11
2018-12-05 Årsstämma 2019
2018-11-01 Bokslutskommuniké 2018
2018-08-08 Kvartalsrapport 2018-Q3
2018-05-07 Halvårsutdelning COLO B 5
2018-05-03 Kvartalsrapport 2018-Q2
2018-02-01 Kvartalsrapport 2018-Q1
2017-12-08 Halvårsutdelning COLO B 10.5
2017-12-07 Årsstämma 2018
2017-11-02 Bokslutskommuniké 2017
2017-08-16 Kvartalsrapport 2017-Q3
2017-05-08 Halvårsutdelning COLO B 4.5
2017-05-03 Kvartalsrapport 2017-Q2
2017-02-01 Kvartalsrapport 2017-Q1
2016-12-06 Halvårsutdelning COLO B 9
2016-12-05 Årsstämma 2017
2016-11-02 Bokslutskommuniké 2016
2016-08-16 Kvartalsrapport 2016-Q3
2016-05-09 Halvårsutdelning COLO B 4.5
2016-05-03 Kvartalsrapport 2016-Q2
2016-02-02 Kvartalsrapport 2016-Q1
2015-12-10 Halvårsutdelning COLO B 8
2015-12-09 Årsstämma 2016
2015-11-03 Bokslutskommuniké 2015
2015-08-11 Kvartalsrapport 2015-Q3
2015-05-07 Halvårsutdelning COLO B 4.5
2015-05-05 Kvartalsrapport 2015-Q2
2015-01-29 Kvartalsrapport 2015-Q1
2014-12-05 Halvårsutdelning COLO B 7.5
2014-12-04 Årsstämma 2015
2014-10-30 Bokslutskommuniké 2014
2014-05-08 Halvårsutdelning
2013-12-06 Halvårsutdelning COLO B 7
2013-05-06 Halvårsutdelning COLO B 3
2011-12-08 Ordinarie utdelning
2010-12-02 Ordinarie utdelning
2009-12-02 Ordinarie utdelning


ListaLarge Cap Copenhagen
Coloplast är verksamma inom medicinteknik. Bolaget är en utvecklare av produkter och tjänster anpassade för människor med olika medicinska tillstånd. Bolagets produktportfölj består av vårdutrustning och används huvudsakligen inom områdena stomi, inkontinens, urologi, samt hud- och sårvård. Idag är bolaget verksamma på en global marknad via egna försäljningskanaler. Bolaget grundades 1954 och har sitt huvudkontor i Humlebæk.
2023-04-24 09:30:00

A new multi-center, prospective, two-phase clinical trial1 supported by Atos Medical, a leading company in laryngectomy care, demonstrates a significant improvement in cough and sputum symptoms, leading to improved sleep, with Provox Life.

In 2020, Atos Medical launched a new range of heat and moisture exchangers (HMEs) and adhesives, aimed at improving pulmonary health and quality of life for people living with a laryngectomy. A growing body of evidence has shown that the superior humidification and breathability of Provox Life HMEs lead to improved clinical outcomes.

People who have undergone a total laryngectomy rely on HMEs to compensate for the lack of upper airway humidification and filtration.  With legacy HMEs, many laryngectomized patients use only one type of HME throughout the day irrespective of activity levels. The objectives of the new clinical study were to examine changes in pulmonary and related symptoms using the new generation of Provox Life HMEs.

The study was a two-phase clinical trial starting with the transition to comparable Provox Life HMEs and usage patterns (stage one).  In the second stage, patients used different types of HMEs based on the activity, aiming for the highest possible humidification day and night. The following results were reported:

  1. During stage one, transitioning to the higher-performing Provox Life HMEs significantly improved overall pulmonary health
  2. During stage two, using the highest humidification HMEs optimally during the day and night further improved pulmonary health
  3. Quality of sleep only improved significantly when Provox Life HMEs were used throughout the day and night
  4. Using the new generation of Provox Life HMEs enhanced HME adherence and facilitated the use of an optimal day and night regimen

The research confirms the potential to improve pulmonary health and related symptoms for laryngectomized patients by using better-performing HMEs. There is also a potential to increase the number of hours HMEs are used per day when using a range of devices with different breathing resistance levels that suit the activity.

"Using the Provox Life range improved cough and sputum symptoms and led to associated benefits including improved sleep. These changes can be attributed to both the enhanced humidification properties of the devices and an increased duration of HME use supported by using devices with different breathing resistance for situational use," said Ph. D. Elizabeth Ward, lead investigator of the clinical study.

"We’re thrilled to see the benefits that this clinical study will bring to the laryngectomy patient community. Data from the study confirms recent research and shows that transitioning to better HMEs has a positive impact on pulmonary health.  Improving pulmonary health and related symptoms such as sleep can also have long term benefits to patient well-being and quality of life. The study underlines the importance of optimizing HME usage patterns and marks another milestone for Provox Life,” said Allana Kelley, Vice President, Medical and Scientific Affairs, Atos Medical.

Peter Mønster
Sr. Media Relations Manager
Tel: +45 4911 2623
E-mail: dkpete@coloplast.com

Aleksandra Dimovska
Director, Investor Relations
+45 4911 2458
E-mail: dkadim@coloplast.com

About Atos Medical

Acquired by Coloplast in 2021, Atos Medical is the Voice and Respiratory division of Coloplast. The global leader in laryngectomy care, Atos Medical is also a leading developer and manufacturer of tracheostomy products. Atos is passionate about making life easier for people living with a neck stoma around the world by providing personalized care and innovative solutions, while clinical research and education of both healthcare professionals and patients are integral parts of the business. For more information, please visit atosmedical.com.

1 Elizabeth C Ward, Kelli Hancock, Jenni Boxall, Clare L. Burns, Ann-Louise Spurgin, Belinda Lehn,4 Juliet Hoey,4 Rachelle Robinson,5 and Adele Coleman: Post-laryngectomy pulmonary and related symptom changes following the adoption of an optimal Day-and-Night Heat and Moisture Exchange (HME) regimen. First published on 20 February 2023, https://doi.org/10.1002/hed.27323